Type of information: Company acquisition
Acquired company: Stelios Therapeutics (USA-CA)
Acquiring company: Lexeo Therapeutics (USA-NY)
clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, announced that it has acquired Stelios Therapeutics, an early-stage company developing novel adeno-associated virus (AAV)-mediated gene therapies for rare genetic cardiac
conditions. Through the agreement, Lexeo obtains exclusive rights to three preclinical AAV-mediated gene therapy programs focused on TNNI3-associated hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC), two rare cardiac
disorders with no approved pharmacological treatments and significant commercial potential.
The acquisition allows Lexeo to expand its pipeline in rare genetic cardiac diseases with the addition of three novel programs. The transaction provides a unique opportunity to integrate Lexeo and Stelios’ complementary capabilities, including Lexeo’s growing infrastructure in clinical development and chemistry, manufacturing and controls (CMC) with an existing focus on rare cardiac diseases, and Stelios’ robust pre-clinical pipeline and domain expertise in rare genetic cardiac diseases. The Stelios programs complement and broaden Lexeo’s advanced pre-clinical gene therapy pipeline in rare cardiac diseases, which currently includes LX2006, an IV-administered, AAV-mediated gene therapy program for the potential treatment of cardiomyopathy associated with Friedreich’s ataxia (FA).
The transaction was approved by the Board of Directors of both companies and closed immediately. Financial terms of the transaction are undisclosed.
Related: Rare diseases - Cardiovascular diseases - gene therapy
Is general: Yes